Cryptophycin 1 cellular levels and effects in vitro using L1210 cells

Investigational New Drugs

Volumn 16, Issue 3, 1998, Pages 199-204

  Foster, Brenda J ^a,b   Fortuna, Mike ^a   Media, Joe ^a   Wiegand, Richard A ^a   Valeriote, Frederick A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Division of Hematology and Oncology   (United States)

Author keywords

Cryptophycin 1 with L1210 cells

Indexed keywords

ANTINEOPLASTIC AGENT; CRYPTOPHYCIN 1; NATURAL PRODUCT; TUBULIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL GROWTH; CELL LEVEL; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG STRUCTURE; LEUKEMIA L 1210; MACROMOLECULE; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RNA SYNTHESIS; TEMPERATURE SENSITIVITY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEPSIPEPTIDES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; PEPTIDES, CYCLIC; TUMOR CELLS, CULTURED;

EID: 0032413584     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006148127527     Document Type: Article

References (14)

1. Cragg GM, Newman DJ, Snader KM: Natural products in drug discovery and development. J Nat Prod 60: 52-60, 1997
2. Stewart CF, Ratain MJ: Topoisomerase interactive agents. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology. 5th Edn. Lippincott-Raven, Philadelphia, 1997, pp 452-467
3. Rowinsky EK, Donehower RC: Antimicrotubule agents. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology. 5th Edn. Lippincott-Raven, Philadelphia, 1997, pp 467-483
4. Schwartz RE, Hirsch CF, Sesin DF, Flor JE, Chartrain M, Fromtling RE, Harris GH, Salvatore MJ, Liesch JM, Yudin K: Pharmaceuticals from cultured algae. J Indust Microbiol 5: 113-124, 1990
5. Golakoti T, Ohtani I, Patterson GML, Moore RE, Corbett TH, Valeriote FA, Demchick L: Total structures of cryptophycins, potent antitumor depsipeptides from blue-green algae Nostac sp. strain GSV224. J Am Chem Soc 116: 4729-4737, 1994
6. Smith CD, Zhang X, Mooberry SL, Patterson GML, Moore RE: Cryptophycin: a new antimicrotubule agent active against drug-resistant cells. Cancer Res 54: 3779-3784, 1994
7. Moore RE, Corbett TH, Patterson GML, Valeriote FA: The search for new antitumor drugs from blue-green algae. Curr Pharmaceut Des 2: 317-330, 1996
8. Corbett TH, Valeriote FA, Demchick L, Lowichik N, Polin L, Panchapor C, Pugh S, White K, Kushner J, Rake J, Wentland M, Golakoti T, Hetzel C, Ogino J, Patterson G, Moore R: Discovery of cryptophycin 1 and BCN-183577: examples of strategies and problems in the detection of antitumor activity in mice. Invest New Drugs 15: 207-218, 1997
9. Bai R, Schwartz RE, Kepler JA, Pettit GR, Hamel E: Characterization of the interaction of cryptophycin 1 with tubulin: binding in the Vinca domain competitive inhibition of dolostatin 10 binding, and an unusual aggregation reaction. Cancer Res 56: 4398-4406, 1996
10. Smith CD, Zhang X: Mechanism of action cryptophycin. Interaction with the vinca alkaloid domain of tubulin. J Biol Chemistry 271: 6192-6198, 1996
11. Corbett TH, Valeriote FA, Polin L, Panchapor C, Pugh S, White K, Lowichik N, Knight J, Bissery MC, Wozniak A, LoRusso P, Biernat L, Polin D, Knight L, Piggar S, Looney D, Demchick L, Jones J, Blain S, Palner K, Essenmaker S, Lisow L, Mattes KC, Cavannaugh PF, Rake JB, Baker L: Discovery of solid tumor active agents using a soft-agar colony-formation disk-diffusion assay. In: Valeriote FA, Corbett TH, Baker LH (eds) Cytotoxic Anticancer Drags: Models and Concepts for Drugs Discovery and Development. Kluwer Academic Publishers, Boston, 1990, pp 33-87
12. LoRusso P, Foster BJ, Poplin E, McCormick J, Kraut M, Flaherty L, Heilbrun L, Valdivieso M, Baker L: Phase I clinical trial of pyrazoloacridine NSC 366140 (PD 115934). Clin Cancer Res 1: 1487-1493, 1995
13. Foster BJ, Jones L, Wiegand R, LoRusso PM, Corbett TH: Preclinical pharmacokinetic, antitumor and toxicity studies with CI-994 (N-acetyldinaline). Invest New Drugs 15: 187-194, 1997
14. Foster BJ, Wiegand RA, Pugh S, LoRusso PM, Rake J, Corbett TH: Pharmacokinetic studies in mice of two new thioxanthenones (183577 and 232759) that showed preferential solid tumor activity. Clin Cancer Res 3: 2047-2053, 1997